Lisi's departure is not attributed to any disagreements with the board or operational issues, which suggests a smooth transition. The company has executed a Separation and Release of Claims Agreement with Lisi, which includes a separation pay of $650,000 over 12 months and coverage for COBRA premiums for the same duration. Additionally, all unvested stock options and awards held by Lisi will immediately vest, allowing him to exercise these options for up to 24 months post-separation.
Goodman brings over 25 years of experience in sales strategy and commercial operations, having previously held leadership roles at notable companies such as BioTelemetry and Thermo Fisher Scientific. His appointment is expected to enhance Beyond Air's commercial growth and market penetration strategies. The board expressed confidence in Goodman’s ability to lead the company through its next phase of growth, particularly in expanding the adoption of its LungFit technology.
The company has not yet finalized an employment agreement with Goodman but intends to negotiate terms promptly. The leadership change is anticipated to have a positive impact on the company’s strategic direction and operational execution, aligning with its goals for growth in the competitive healthcare sector. Beyond Air's focus on leveraging its innovative technology positions it well for future success in the market.
